{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05226494",
            "orgStudyIdInfo": {
                "id": "NP-100-101"
            },
            "organization": {
                "fullName": "NanoPharmaceuticals LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma",
            "officialTitle": "A Phase 1 Trial to Evaluate the Safety and Tolerability of Fb-PMT in Patients With Recurrent Glioblastoma",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "safety-and-tolerability-of-fb-pmt-in-recurrent-glioblastoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-06-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-12-03",
            "studyFirstSubmitQcDate": "2022-01-25",
            "studyFirstPostDateStruct": {
                "date": "2022-02-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "NanoPharmaceuticals LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma."
        },
        "conditionsModule": {
            "conditions": [
                "Glioma, Malignant"
            ],
            "keywords": [
                "Glioblastoma",
                "Glioblastoma Multiforme"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "3+3 Dose Escalation with option for cohort expansion",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 34,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Treatment (fb-PMT)",
                    "type": "EXPERIMENTAL",
                    "description": "Daily subcutaneous injection of fb-PMT in four escalating cohorts to determine maximum tolerated dose, followed by treatment of up to 10 additional patients at maximum tolerated dose.",
                    "interventionNames": [
                        "Drug: fb-PMT"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "fb-PMT",
                    "description": "Daily dosing based on patient weight",
                    "armGroupLabels": [
                        "Treatment (fb-PMT)"
                    ],
                    "otherNames": [
                        "NP-100",
                        "NP751"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]",
                    "description": "Determined by the number of Treatment-Emergent Adverse Events, including Dose-Limiting Toxicities per patient.",
                    "timeFrame": "15 months"
                },
                {
                    "measure": "Incidence of Dose Limiting Toxicities [Safety and Tolerability]",
                    "description": "Number of participants with a dose-limiting toxicity during the first cycle (28 days) of treatment at their highest dose level administered.",
                    "timeFrame": "28 Days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Establishment of Recommended Phase 2 Dose",
                    "description": "Maximum Tolerated Dose, as determined by Dose-Limiting Toxicities.",
                    "timeFrame": "28 Days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven intracranial glioblastoma, with first or second recurrence\n* On stable or decreasing dose of steroids, if taken prior to screening\n* Baseline MRI (with and without contrast) completed with 5 days of starting fb-PMT\n* Prior completion of and recovery from the effects of standard of care for glioblastoma management with surgery/biopsy and radiotherapy\n* Confirmation of true progressive disease for patients previously treated with interstitial brachytherapy or stereotactic radio surgery\n* Life expectancy of more than three months\n* Karnofsky Performance Status of \u2265 70\n* Hypertension must be well controlled (\u2264 95th percentile) on stable doses of medication\n* Adequate bone marrow and organ function, confirmed by laboratory testing at screening\n* Patient or caregiver must be able to store drug under refrigerated conditions, prepare and administer daily subcutaneous injections on a set schedule, and record information in a daily treatment diary\n* Women of childbearing potential must agree to ongoing pregnancy testing and to use medically acceptable contraception for the duration of the study and for 2 months after their last dose of study drug\n* Males must agree to use medically acceptable contraception and refrain from donating sperm for the duration of the study and for 2 months after their last dose of study drug\n\nExclusion Criteria:\n\n* Significant medical illness that is uncontrolled, may obscure toxicity, may dangerously alter drug metabolism, or may compromise ability for study participation\n* History of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for at least 3 months prior to first dose of study drug\n* Use of bevacizumab or any other experimental drug or therapy within 28 days of study treatment\n* Prior therapy with fb-PMT or related drugs\n* Currently pregnant or breastfeeding\n* Active infection or serious intercurrent medical illness\n* Surgery of any type within the preceding 28 days that has not fully healed\n* A serious or non-healing wound, ulcer, or bone fracture\n* A known bleeding diathesis or coagulopathy, or a history of bleeding diathesis within 28 days of study treatment\n* A known thrombophilic condition (i.e., protein S, protein C, or antithrombin III deficiency, Factor V Leiden, Factor II G20210A mutation, homocysteinemia or antiphospholipid antibody syndrome). Testing is not required in patients without thrombophilic history.\n* Evidence of new central nervous system hemorrhage on baseline MRI obtained within 14 days prior to study enrollment\n* Clinically significant cardiovascular event such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening.\n* New York Heart Association classification of heart disease greater than Class 2\n* QTc interval \\> 450 msec in males or \\> 470 msec in females at screening\n* Use of concomitant medications that prolong the QT/QTc interval or risk inducing Torsades de Pointes\n* Use of any concomitant OATP1B1, OATP1B3, or BSEP inhibitors within 14 days or five half-lives (whichever is longer) before starting study drug treatment\n* Abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to study enrollment\n* A significant vascular disease (e.g., aortic aneurysm requiring surgical repair, deep venous or arterial thrombosis) within the last 6 months prior to study enrollment\n* History of stroke, myocardial infarction, transient ischemic attack (TIA), severe or unstable angina, peripheral vascular disease, or grade II or greater congestive heart failure within the past 6 months\n* History of Torsades de Pointes or risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Adam Blanchard",
                    "role": "CONTACT",
                    "phone": "(203) 499-9297",
                    "email": "adam.blanchard@yale.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Nicholas Blondin, MD",
                    "affiliation": "Yale University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Smilow Cancer Hospital",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06511",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Nicholas Blondin, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005909",
                    "term": "Glioblastoma"
                },
                {
                    "id": "D000005910",
                    "term": "Glioma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001254",
                    "term": "Astrocytoma"
                },
                {
                    "id": "D000018302",
                    "term": "Neoplasms, Neuroepithelial"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9020",
                    "name": "Glioma",
                    "asFound": "Glioma, Malignant",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M9019",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4561",
                    "name": "Astrocytoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M20446",
                    "name": "Neoplasms, Neuroepithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "T2519",
                    "name": "Glioma",
                    "relevance": "LOW"
                },
                {
                    "id": "T2518",
                    "name": "Glioblastoma",
                    "asFound": "Glioblastoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}